Document is current
Any future updates will be listed below
-
Authors
Barbui, Tiziano https://orcid.org/0000-0003-2747-6327
Ghirardi, Arianna
Empson, Victoria
Fenili, Francesca
Loscocco, Giuseppe Gaetano https://orcid.org/0000-0002-6241-1206
Condorelli, Annalisa
Iurlo, Alessandra https://orcid.org/0000-0002-4401-0812
Cattaneo, Daniele
Rossi, Elena
De Stefano, Valerio https://orcid.org/0000-0002-5178-5827
Guglielmelli, Paola https://orcid.org/0000-0003-1809-284X
Klade, Christoph
Gisslinger, Heinz https://orcid.org/0000-0002-0295-7629
Rambaldi, Alessandro https://orcid.org/0000-0002-3739-7502
Scandura, Joseph M.
Vannucchi, Alessandro Maria https://orcid.org/0000-0001-5755-0730
- License Information
-
More Information
Article History
Received: 24 March 2025
Revised: 13 May 2025
Accepted: 9 June 2025
First Online: 6 August 2025
Competing interests
: TB: Research grant from GSK and AOP. Advisory Board AOP and Italfarmaco. VE and CK are employees of AOP Orphan Pharmaceuticals. GGL: Speaker’s bureau from Novartis and GSK. AI: Speaker honoraria from AOP Health, BMS, GSK, Incyte, Novartis and Pfizer. ER: Advisory Board AOP Health. VDS: Advisory Board AOP Health. PG: Advisory Board Novartis, Incyte and GSK; Speaker’s bureau for Novartis, Gsk, Abbvie, AOP. AMV: Advisory Board and/or lectures from Novartis, AbbVie, AOP Pharmaceuticals, BMS and Incyte. HG: grants and/or personal fees from AOP Health, Novartis, and BMS-Pharma. AR: fees for consultancies and participation in meetings, boards, and symposia sponsored by Amgen, Pfizer, Novartis, Kite‐Gilead, Jazz, Astellas, Abbvie, Incyte, and Omeros. JMS: Advisory Board or Consultant for Abbvie, Incyte, Protagonist, Novartis, SDP Oncology and Karyopharm. AG, FF, AC and DC have no conflicts of interest to declare.
